|
Market Research Report
Strategic Analysis of Opportunities in the CRO Market - Phase 0
| Published by |
Frost & Sullivan |
| Published |
September, 2008 |
Product code |
74746 |
| Content info |
48 Pages |
| Price |
|
|
Strategic Analysis of Opportunities in the CRO Market - Phase 0 published by Frost & Sullivan in September, 2008. This report consists of 48 Pages and the price starts from US $ 6500.
Abstract
This strategic analysis study attempts to understand the opportunities for
contract research organisations and pharmaceutical companies to take advantage
of the inevitable choice of Phase zero or Microdosing studies in the drug
development process. The background of microdosing, industry challenges,
regulatory guidelines and competitive analysis are discussed in detail.
Table of Contents
1. RESEARCH METHODOLOGY
Research Process
2. INDUSTRY CHALLENGES
Challenges faced by the CROs
- Consolidation within the CRO Industry to Threaten Customer Relationship
- Electronic Data Capture Threatens Revenues
- Risk Sharing Model Necessitates Proper Positioning of Services
- Regional Disparities Affect Competitive Pricing of Services
3. MARKET OVERVIEW
Phase Zero
- CRO Contribution to Drug Development
- Human Microdosing
- Technologies used in Microdosing
- Advantages of Microdosing
- FDA and EMEA Regulations
- The EUMAPP Program
- Concerns about Microdosing
- Revenue Forecasts
- Future Outlook
Profiles of Key Industry Participants
- Accium Biosciences
- Radiant Research
- Vitalea Science
- Xceleron
4. STRATEGIC RECOMMENDATIONS
Approaches to Microdosing
- Alternative Applications of Microdosing
5. DECISION SUPPORT DATABASES
DSD Tables
- Number of Biotech Companies
- Government R&D Investment in Biotechnology
- Percent Government Biotech R & D Investment
- Pharmaceutical R & D Expenditure
|
